European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact

Value of PSA screening assessed at World Chinese Joint Session

Fri, 11 Apr 2014

As part of the World Chinese Joint Session, organized for the very first time at the EAU Congress, the advantages and disadvantages of PSA screening for prostate cancer were discussed from the European and Asian perspectives. Prof. Per-Anders Abrahamsson (SE) mentioned how early detection can reduce cancer-specific mortality. Dr. Tai-Lung Cha (TW) focused on the dangers of overdiagnosis.

“PSA screening has been a controversial topic for decades and initially Europe was reluctant to implement it,” said Abrahamsson. “Based on new data from big studies I predict that early detection will reduce cancer-related deaths in the future.”

Studies show that men whose PSA level is below 1.0 ng/mL at age 60 have a 0.2% risk of dying from prostate cancer. Abrahamsson advocated for establishing the PSA baseline at age 45. Screening will go hand in hand with improved imaging technology and better treatment techniques.

Cha interpreted the available data from the Asian perspective in his presentation about PSA screening in Taiwan, where cancer-related mortality is relatively low.

Cha warned against overdiagnosis and overtreatment and advised screening should focus on high risk cases. He pointed to the risk of biopsy-related complications, the psychological effects for patients, and the cost-effectiveness of screening and subsequent treatment.

Abrahamsson commented that mortality rates for prostate cancer in Northern Europe are among the highest in the world. He agreed with Cha that, regardless of mortality rates, over diagnosis remains a problem of screening.

Share this article

About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact
  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer